Loading stock data…
Aktis Oncology, Inc. (AKTS)
$27.05+0.40 (+1.50%)
Pre-Market$25.98-1.07 (-3.96%)· Last close Sep 4
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $3.23M↑ | $1.87M | — | $1.45M↑ | $933,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$22.71M↓ | -$17.38M | — | -$18.14M↓ | -$15.63M |
| Net Income | -$18.32M↓ | -$15.14M | — | -$14.98M↓ | -$12.06M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-11...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.07B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.95%
Volume
Today's trading volume
159,248
Recent News
Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
Aktis Oncology (AKTS) is well positioned to build a new class of targeted radiation-based cancer dru
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound
What recent performance says about Aktis Oncology Aktis Oncology (AKTS) has drawn fresh attention after recent trading, with the stock up 6.4% on the day and 9.3% over the past week, even as it is down 4.3% over the past month. See our latest analysis for Aktis Oncology. For context, Aktis Oncology’s recent 1 day share price return of 6.38% and 7 day share price return of 9.30% come after a 30 day share price return that is down 4.33% and a year to date share price return that is down 9.20%...
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.
Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors
Aktis Oncology (NASDAQ:AKTS) outlined its clinical development strategy for AKY-2519, a B7-H3 targeted miniprotein radioconjugate, emphasizing a two-trial approach intended to generate indication-specific data in metastatic castration-resistant prostate cancer (mCRPC) while also exploring broader po